Subject:  Biotechnology Concern Posts Loss for Quarter and Year
Date: Published: 11/18/92 (30 lines)
Source: Wall Street Journal. Copyright Dow Jones & Co. Inc.

    Business Brief -- Epitope Inc.:
    Biotechnology Concern Posts
    Loss for Quarter and Year

    Citing higher research and development costs, Epitope Inc. 
 reported a wider loss for the fiscal fourth quarter and the year.
    For the quarter ended Sept. 30, the biotechnology concern posted
 a net loss of $2.3 million, or 27 cents a share, on revenue of
 $784,000, compared with a year-earlier loss of $1.8 million, or 23
 cents a share, on revenue of $650,000.
    Epitope has only one product now on the market, a confirmatory
 AIDS test called EPIblot.  The company's agricultural unit, Agritope,
 recently conducted field trials of genetically engineered tomatoes,
 intended to have longer shelf life.
    For the year, the Beaverton, Ore., company posted a net loss of
 $7.2 million, or 83 cents a share, on revenue of $3 million, vs. a
 net loss of $4.9 million, or 64 cents a share, on revenue of $3.8
 million a year earlier.  Epitope said full-year revenue was down
 because of lower sales of its AIDS test in the first six months.
 Research and development costs for the year were $4.4 million, up
 22% from the prior year.

[This article is made available here by Dow Jones Co. for the
 personal and non-commercial use of callers to this bbs, in the
 hope that it will be of some help to those who are suffering
 from the disease and others who are seeking to help them.]